NCT03082833

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Samsung Medical Center

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line chemotherapy

Detailed description

AZD2014 50mg BD continuous schedule of a 28 day cycle AZD2014 will be administered with orange juice in STG/TG patients. AZD2014 can be taken with or without food. The first dose of the day should be taken at approximately the same time each morning.The second dose of the day should be taken approximately 12 hours after the morning dose.

Conditions

• Cancer of Stomach

Interventions

Type	Name	Description
DRUG	AZD2014	AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).

Timeline

• Start date: 2017-02-01
• Primary completion: 2018-11-16
• Completion: 2018-11-16
• First posted: 2017-03-17
• Last updated: 2019-05-20

Locations

1 site across 1 country: South Korea